Chiusura precedente | 3,7600 |
Aperto | 3,7000 |
Denaro | 1,8000 |
Domanda | 5,8000 |
Prezzo d'esercizio | 77,50 |
Scadenza | 2024-12-20 |
Min-Max giorno | 3,7000 - 3,7600 |
Contratto - Min-Max | N/D |
Volume | |
Open Interest | 7 |
NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Susan Mahony, PhD, has been appointed to Axsome’s board of directors, effective immediately. Dr. Mahony most recently served on the board of directors of Horizon Therapeutics from 2019 until its acquisition by Amgen in October 2023. She was formerly Senior Vice
Axsome to host conference call and webcast on Monday, Nov. 6, 2023, at 8:00 a.m. Eastern TimeNEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the third quarter of 2023 on Monday, Nov. 6, 2023, before the opening of the U.S. financial markets. Axsome’s management team w
NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced it is joining patient advocacy organizations, including the National Alliance on Mental Illness (NAMI), to promote awareness of the importance of mental health during Mental Illness Awareness Week (MIAW), recognized on Oct. 1-7, 2023. As part of Axsome’s commitment